© 2022 MJH Life Sciences and HCPLive - Clinical news for connected physicians. All rights reserved.
© 2022 MJH Life Sciences™ and HCPLive - Clinical news for connected physicians. All rights reserved.
Jerry Bagel, MD, MS, discusses the management of moderate-to-severe plaque psoriasis with a focus on newer agents currently in the drug approval pipeline.
February 18th 2022
Jerry Bagel, MD, MS, provides an overview of potential challenges in managing plaque psoriasis and assess to biologics utilized in plaque psoriasis.
Jerry Bagel, MD, MS, discuss new targets, treatment goals, and utilizing shared decision making when treating patients with plaque psoriasis.
February 25th 2022
An expert dermatologist details the effect of the COVID-19 pandemic and other comorbidities on treatment selection for plaque psoriasis.
Dr Jerry Bagel describes the unmet needs of plaque psoriasis management.
March 4th 2022
An overview of the novel selective tyrosine kinase 2 (TYK2) inhibitor deucravacitinib for the management of plaque psoriasis.
Jerry Bagel, MD, MS, explains clinical trial data on the investigational anti-IL17A/F monoclonal antibody bimekizumab.
March 11th 2022
Dr Jerry Bagel looks to the future of moderate-to-severe plaque psoriasis management.
Organizations Call on FDA To Help Address Recurrent C Difficile Burdens
Wonder Drake, MD: Understanding the Progression Patterns of Sarcoidosis
Presence of Residual Subretinal Fluid May Be Linked to Better BCVA in nAMD Treatment